Role of Serotonin (5-HT) in GDM Prediction Considering Islet and Liver Interplay in Prediabetic Mice During Gestation
Overview
Chemistry
Molecular Biology
Affiliations
Gestational diabetes (GDM) is characterized by a glucose tolerance disorder. This may first appear during pregnancy or pre-exist before conception as a form of prediabetes, but there are few data on the pathogenesis of the latter subtype. Female New Zealand obese (NZO) mice serve as a model for this subpopulation of GDM. It was recently shown that GDM is associated with elevated urinary serotonin (5-hydroxytryptamine, 5-HT) levels, but the role of the biogenic amine in subpopulations with prediabetes remains unclear. 5-HT is synthesized in different tissues, including the islets of Langerhans during pregnancy. Furthermore, 5-HT receptors (HTRs) are expressed in tissues important for the regulation of glucose homeostasis, such as liver and pancreas. Interestingly, NZO mice showed elevated plasma and islet 5-HT concentrations as well as impaired glucose-stimulated 5-HT secretion. Incubation of isolated primary NZO islets with 5-HT revealed an inhibitory effect on insulin and glucagon secretion. In primary NZO hepatocytes, 5-HT aggravated hepatic glucose production (HGP), decreased glucose uptake (HGU), glycogen content, and modulated AKT activation as well as cyclic adenosine monophosphate (cAMP) increase, indicating 5-HT downstream modulation. Treatment with an HTR2B antagonist reduced this 5-HT-mediated deterioration of the metabolic state. With its strong effect on glucose metabolism, these data indicate that 5-HT is already a potential indicator of GDM before conception in mice.
Asuaje Pfeifer M, Langehein H, Grupe K, Muller S, Seyda J, Liebmann M Front Endocrinol (Lausanne). 2023; 14:1250023.
PMID: 37772078 PMC: 10523144. DOI: 10.3389/fendo.2023.1250023.
Mouse Models of Gestational Diabetes Mellitus and Its Subtypes: Recent Insights and Pitfalls.
Grupe K, Scherneck S Int J Mol Sci. 2023; 24(6).
PMID: 36983056 PMC: 10058162. DOI: 10.3390/ijms24065982.
Liebmann M, Grupe K, Asuaje Pfeifer M, Rustenbeck I, Scherneck S Lipids Health Dis. 2022; 21(1):99.
PMID: 36209101 PMC: 9547403. DOI: 10.1186/s12944-022-01706-x.